Augustine Asset Management Inc. Boosts Holdings in Sanofi (NASDAQ:SNY)

Augustine Asset Management Inc. increased its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 166.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 81,945 shares of the company's stock after buying an additional 51,198 shares during the period. Sanofi comprises 1.8% of Augustine Asset Management Inc.'s investment portfolio, making the stock its 16th largest holding. Augustine Asset Management Inc.'s holdings in Sanofi were worth $4,075,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in SNY. Rise Advisors LLC grew its holdings in Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company's stock worth $25,000 after acquiring an additional 251 shares in the last quarter. SRS Capital Advisors Inc. grew its holdings in Sanofi by 289.1% during the 1st quarter. SRS Capital Advisors Inc. now owns 463 shares of the company's stock worth $25,000 after acquiring an additional 344 shares in the last quarter. Householder Group Estate & Retirement Specialist LLC acquired a new position in Sanofi during the 3rd quarter worth approximately $26,000. Fairfield Bush & CO. acquired a new position in Sanofi during the 1st quarter worth approximately $26,000. Finally, Indiana Trust & Investment Management CO acquired a new position in Sanofi during the 3rd quarter worth approximately $27,000. 10.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SNY has been the subject of several analyst reports. TheStreet cut shares of Sanofi from a "b" rating to a "c" rating in a report on Friday, February 9th. Morgan Stanley started coverage on shares of Sanofi in a report on Tuesday, January 23rd. They issued an "equal weight" rating and a $55.00 target price for the company. Finally, StockNews.com cut shares of Sanofi from a "strong-buy" rating to a "buy" rating in a report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $55.00.

Sanofi Stock Down 1.2 %

Shares of Sanofi stock traded down $0.55 during trading hours on Friday, hitting $47.25. The company had a trading volume of 1,289,138 shares, compared to its average volume of 1,495,971. The company's 50-day moving average is $47.84 and its two-hundred day moving average is $49.10. Sanofi has a twelve month low of $42.63 and a twelve month high of $57.82. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The company has a market cap of $119.52 billion, a P/E ratio of 20.02, a price-to-earnings-growth ratio of 1.77 and a beta of 0.61.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a net margin of 12.56% and a return on equity of 27.47%. The business had revenue of $11.76 billion during the quarter, compared to analysts' expectations of $13.02 billion. Analysts anticipate that Sanofi will post 4.19 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be given a $1.478 dividend. This is an increase from Sanofi's previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. This represents a yield of 2.98%. Sanofi's dividend payout ratio is 58.47%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.